Literature DB >> 21815142

Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva.

Lindy A M Santegoets1, Romy van Baars, Annelinde Terlou, Claudia Heijmans-Antonissen, Sigrid M A Swagemakers, Peter J van der Spek, Patricia C Ewing, Marc van Beurden, Willem I van der Meijden, Theo J M Helmerhorst, Leen J Blok.   

Abstract

Human papillomavirus (HPV) infections may result in benign hyperplasia, caused by low-risk HPV types, or (pre)malignant lesions caused by high-risk HPV types. The molecular basis of this difference in malignant potential is not completely understood. Here, we performed gene profiling of different HPV infected vulvar tissues (condylomata acuminata (n = 5), usual type vulvar intraepithelial neoplasia (uVIN) (n = 9)) and control samples (n = 14) using Affymetrix Human U133A plus 2 GeneChips. Data were analyzed using OmniViz®, Partek® and Ingenuity® Software. Results were validated by real-time RT-PCR and immunostaining. Although similarities were observed between gene expression profiles of low- and high-risk HPV infected tissues (e.g., absence of estrogen receptor in condylomata and uVIN), high-risk HPV infected tissues showed more proliferation and displayed more DNA damage than tissues infected with low-risk HPV. These observations were confirmed by differential regulation of cell cycle checkpoints and by increased expression of DNA damage-biomarkers p53 and γH2AX. Furthermore, FANCA, FANCD2, BRCA1 and RAD51, key players in the DNA damage response, were significantly upregulated (p < 0.05). In addition, we compared our results with publicly available gene expression profiles of various other HPV-induced cancers (vulva, cervix and head-and-neck). This showed p16(INK4a) was the most significant marker to detect a high-risk HPV infection, but no other markers could be found. In conclusion, this study provides insight into the molecular basis of low- and high-risk HPV infections and indicates two main pathways (cell cycle and DNA damage response) that are much stronger affected by high-risk HPV as compared to low-risk HPV.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21815142     DOI: 10.1002/ijc.26345

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma.

Authors:  Jessica C Hassel; Leopold Groesser; Eva Herschberger; Wilko Weichert; Christian Hafner
Journal:  J Invest Dermatol       Date:  2014-07-18       Impact factor: 8.551

2.  Oral human papillomavirus is common in individuals with Fanconi anemia.

Authors:  Sharon L Sauter; Susanne I Wells; Xue Zhang; Elizabeth E Hoskins; Stella M Davies; Kasiani C Myers; Robin Mueller; Gitika Panicker; Elizabeth R Unger; Umasundari Sivaprasad; Darron R Brown; Parinda A Mehta; Melinda Butsch Kovacic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-03-25       Impact factor: 4.254

3.  Design stars: how small DNA viruses remodel the host nucleus.

Authors:  Mengxi Jiang; Michael J Imperiale
Journal:  Future Virol       Date:  2012-05-01       Impact factor: 1.831

4.  Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification.

Authors:  Tormi Reinson; Mart Toots; Meelis Kadaja; Regina Pipitch; Mihkel Allik; Ene Ustav; Mart Ustav
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

5.  Expression of HPV-induced DNA Damage Repair Factors Correlates With CIN Progression.

Authors:  Chelsey C Spriggs; Luis Z Blanco; Kruti P Maniar; Laimonis A Laimins
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

6.  Integrative analyses reveal novel strategies in HPV11,-16 and -45 early infection.

Authors:  Bogumil Kaczkowski; Maria Rossing; Ditte K Andersen; Anita Dreher; Marya Morevati; Melissa A Visser; Ole Winther; Finn Cilius Nielsen; Bodil Norrild
Journal:  Sci Rep       Date:  2012-07-17       Impact factor: 4.379

Review 7.  VIN usual type-from the past to the future.

Authors:  Mario Preti; Sarah Igidbashian; Silvano Costa; Paolo Cristoforoni; Luciano Mariani; Massimo Origoni; Maria T Sandri; Sara Boveri; Noemi Spolti; Laura Spinaci; Francesca Sanvito; Eleonora P Preti; Adriana Falasca; Gianluigi Radici; Leonardo Micheletti
Journal:  Ecancermedicalscience       Date:  2015-04-29

Review 8.  Risk of Human Papillomavirus Infection in Cancer-Prone Individuals: What We Know.

Authors:  Ruby Khoury; Sharon Sauter; Melinda Butsch Kovacic; Adam S Nelson; Kasiani C Myers; Parinda A Mehta; Stella M Davies; Susanne I Wells
Journal:  Viruses       Date:  2018-01-20       Impact factor: 5.048

9.  A Decade of Global mRNA and miRNA Profiling of HPV-Positive Cell Lines and Clinical Specimens.

Authors:  Bogumil Kaczkowski; Marya Morevati; Maria Rossing; Finn Cilius; Bodil Norrild
Journal:  Open Virol J       Date:  2012-12-28

10.  Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells.

Authors:  Kalliopi I Pappa; Alexander Polyzos; Jasmine Jacob-Hirsch; Ninette Amariglio; George D Vlachos; Dimitrios Loutradis; Nicholas P Anagnou
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.